Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

BACKGROUND: Bevacizumab (BEV) plus triplet chemotherapy can increase efficacy of first-line treatment of metastatic colorectal cancer (MCRC), particularly integrated with secondary liver surgery in liver-limited (L-L) patients. The prognostic value of the KRAS genotype in L-L and other or multiple m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruera, Gemma, Cannita, Katia, Di Giacomo, Daniela, Lamy, Aude, Troncone, Giancarlo, Dal Mas, Antonella, Coletti, Gino, Frébourg, Thierry, Sabourin, Jean Christophe, Tosi, Mario, Ficorella, Corrado, Ricevuto, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520760/
https://www.ncbi.nlm.nih.gov/pubmed/23136868
http://dx.doi.org/10.1186/1741-7015-10-135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520760/
https://www.ncbi.nlm.nih.gov/pubmed/23136868
http://dx.doi.org/10.1186/1741-7015-10-135

Ejemplares similares